phrykt

BridgeBio Oncology Therapeutics, Inc. (BBOT): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of BBOT were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling BridgeBio Oncology Therapeutics

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns BBOT

67 funds and institutions reported BBOT shares worth $453M at the end of Q2 2026, about 74% of the company. The largest holder is Cormorant Asset Management, LP with 22.3%.

Funds and institutions (13F) 74%Everyone else 26%

10 largest owners, by share of the company

Cormorant Asset Management, LP22.3%
Deerfield Management Company, L.P.6.1%
Omega Fund Management, LLC4.1%
EcoR1 Capital, LLC3.5%
Alphabet Inc.3.5%
Wellington Management Group LLP3.5%
Enavate Sciences Gp, LLC3.3%
Citadel Advisors LLC3.3%
Novo Holdings A/s2.8%
BlackRock, Inc.2.7%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Cormorant Asset Management, LP17.88M22.34%$136MNo change
Deerfield Management Company, L.P.4.89M6.10%$37.2MNo change
Omega Fund Management, LLC3.29M4.11%$25.1MNo change
EcoR1 Capital, LLC2.82M3.53%$21.5MNo change
Alphabet Inc.2.82M3.53%$21.5MNo change
Wellington Management Group LLP2.79M3.49%$21.3M-1%
Enavate Sciences Gp, LLC2.63M3.28%$20MNo change
Citadel Advisors LLC2.62M3.27%$19.9M+4%
Novo Holdings A/s2.25M2.81%$17.1M+3%
BlackRock, Inc.2.15M2.69%$16.4M+3%
Vanguard Capital Management LLC2.01M2.51%$15.3M+272%
Laurion Capital Management LP2.00M2.50%$15.3M+4%
Armistice Capital, LLC1.76M2.20%$13.4M+33%
State Street Corp1.04M1.30%$7.9M+358%
Aisling Capital Management LP1.02M1.27%$7.8MNo change
Opaleye Management Inc.700,0000.87%$5.3M+1214%
Geode Capital Management, LLC622,3510.78%$4.7M+7%
Granahan Investment Management, LLC558,5260.70%$4.3M+142%
Sphera Funds Management Ltd.460,9850.58%$3.5MNew
Adage Capital Partners Gp, L.l.c.400,0000.50%$3MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No BBOT insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

BBOT short interest

Low short interest. 4.3% of BBOT shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went up 6%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 3.47M BBOT shares were sold short, 4.3% of the shares outstanding, down 9.8% from the report before. At the average daily volume of 680,248 shares, buying them all back would take about 5.1 trading days (days to cover).

Shares short, % of all shares

4.33%May 15Oct 308.27%

Days to cover

5.1May 15Oct 3027.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20263.47M4.33%-10%680,2485.1
Oct 15, 20263.85M4.80%+14%542,6517.1
Sep 30, 20263.37M4.21%-6%624,6575.4
Sep 15, 20263.60M4.49%-42%824,8224.4
Aug 31, 20266.19M7.73%+7%298,24920.8
Aug 14, 20265.81M7.24%-0%234,20724.8
Jul 31, 20265.83M7.28%+2%280,56320.8
Jul 15, 20265.69M7.11%+9%451,43412.6
Jun 30, 20265.21M6.51%+32%726,3727.2
Jun 15, 20263.94M4.92%+2%251,62915.7
May 29, 20263.87M4.83%+18%464,3058.3
May 15, 20263.28M4.09%-1%323,70110.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

BridgeBio Oncology Therapeutics company events

BridgeBio Oncology Therapeutics filed 11 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 10, 2026.

  1. Nov 10, 2026ResultsReleased financial results. Filing
  2. Nov 5, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  3. Sep 8, 2026AnnouncementBridgeBio Oncology Therapeutics, Inc. issued a press release titled “ BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers .” A copy of the press release is attached as Exhibit 99.1 to… Filing
  4. Aug 11, 2026ResultsReleased financial results. Filing
  5. Jun 22, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  6. May 12, 2026ResultsReleased financial results. Filing
  7. Apr 29, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  8. Apr 23, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  9. Mar 26, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  10. Mar 5, 2026ResultsReleased financial results. Filing
  11. Jan 7, 2026AnnouncementBridgeBio Oncology Therapeutics, Inc. issued a press release titled “ BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3K α Pipeline Programs .” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

BridgeBio Oncology Therapeutics financials

Famous investors that hold BBOT

4 of the 50 well-known investors we track reported holding BBOT in their latest 13F filing. The largest position is Ken Griffin's, worth $11.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20262.70M$11.1M0.0%+3%
Israel Englander · Millennium ManagementQ3 2026144,430$592K0.0%+37%
Jim Simons · Renaissance TechnologiesQ3 202664,000$262K0.0%+9%
Steve Cohen · Point72 Asset ManagementQ3 202629,570$121K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BBOT in the last 120 days.

FiledHolderFormStake
Nov 13, 2026Deerfield Mgmt, L.P.13G/A2.0%
Nov 13, 2026Deerfield Mgmt, L.P.13G/A2.0%

Questions about BridgeBio Oncology Therapeutics, Inc. (BBOT) stock

Who owns the most BBOT stock?

The largest reported owner of BridgeBio Oncology Therapeutics, Inc. (BBOT) is Cormorant Asset Management, LP, with 22.3% of the company. In total, 67 funds and institutions reported holding BBOT at the end of Q2 2026, together about 74% of the shares. See the largest owners.

Are BBOT insiders buying or selling?

No BBOT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in BBOT?

As of Oct 30, 2026, 3.47M BBOT shares were sold short, 4.3% of the shares outstanding, down 9.8% from the report before. At the average daily volume of 680,248 shares, buying them all back would take about 5.1 trading days (days to cover). See the history.

Which famous investors hold BBOT?

4 of the 50 well-known investors we track reported BBOT in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $11.1M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.